Endo Efficacy 5pct

---
name: endo-efficacy-5pct
description: This skill guides clinicians to assess whether a patient has achieved ≥5% weight loss at 3 months while on a weight‑loss medication and to determine continuation versus discontinuation based on efficacy and safety. It is triggered when a clinician asks, 'Has this patient lost enough weight at 3 months to continue lorcaserin?' or 'Should I stop phentermine/topiramate because the patient lost only 3% of body weight?'.
---

# Assess efficacy at 3 months using ≥5% weight loss threshold

## STEP 1 — Gather Information
- Record baseline weight (before starting medication) and current weight at 3 months.
- Calculate percent weight loss: ((baseline – current) / baseline) × 100.
- Document any adverse events, vital sign changes, or lab abnormalities that affect safety/tolerability.
- Identify the specific weight‑loss medication being evaluated.
**Action:** Proceed to efficacy/safety decision with % loss and safety profile.

## STEP 2 — Rule In / Rule Out
- If percent weight loss ≥5% AND no safety/tolerability concerns → **continue** medication.
- If percent weight loss <5% OR any safety/tolerability issue → proceed to evaluate discontinuation.
**Action:** Determine whether to continue or move to discontinuation pathway.

## STEP 3 — Classify or Stratify
- For patients with <5% weight loss or safety issues, classify as **inadequate response**.
- Note whether the issue is primarily efficacy (insufficient loss) or tolerability/safety.
**Action:** Prepare to discontinue medication and consider alternatives.

## STEP 4 — Decide
- Discontinue the current weight‑loss medication.
- Discuss alternative pharmacologic options or referral for intensive lifestyle intervention, bariatric surgery evaluation, or multidisciplinary obesity management.
**Action:** Stop medication and initiate alternative plan.

## Clinical Guardrails / Mimics / Pitfalls
- Do not continue a medication solely because of weight loss if new safety signals (e.g., elevated BP, heart rate, mood changes) appear.
- Avoid basing the decision on self‑reported weight; use measured weight on a calibrated scale.
- Remember that a <5% loss may still be meaningful in some patients, but per guideline the threshold for recommending continuation is ≥5% at 3 months.
- Be aware of pregnancy contraindications for agents like phentermine/topiramate and lorcaserin; ensure a pregnancy test if applicable before continuing.
- Do not overlook the need for lifestyle modification reinforcement when discontinuing pharmacotherapy.

## Concrete Clinical Example
A 45‑year‑old woman started lorcaserin 10 mg BID. Baseline weight 92 kg; weight at 3 months is 87 kg (5.4% loss). She reports mild dry mouth only, no hypertension or mood changes. **Decision:** Continue lorcaserin and reinforce lifestyle changes.  
Another example: A 52‑year‑old man on phentermine/topiramate ER 7.5/46 mg daily. Baseline weight 110 kg; weight at 3 months is 107 kg (2.7% loss). He reports constipation and mild insomnia. **Decision:** Discontinue phentermine/topiramate, discuss alternative agents (e.g., GLP‑1 agonist) or referral to a weight‑management program.

**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, doi:10.1210/jc.2014-3415